A drug company is facing a challenge over its chewable contraceptive pill.
US firm Warner Chilcott has received a paragraph IV certification notice from another US company, Barr Laboratories.
Barr filed an abbreviated new drug application (ANDA) for a generic version of Femcon Fe® (norethindrone), the patent for which expires in 2019.
Warner Chilcott, based in New Jersey, is a speciality company focused on manufacturing, marketing and selling branded prescription products in women’s healthcare and dermatology in the US.
Barr, based in New York, is a global firm engaged in developing both generic and proprietary pharmaceuticals.
Paragraph IV certification begins a process in which the question of whether a patent is valid or will be infringed by the proposed generic product may be studied by the courts prior to the patent’s expiry.
When an ANDA applicant files a paragraph IV for a listed patent, the applicant must also notify the patent owner.
The notice must include a statement of the factual and legal basis for the ANDA applicant’s opinion that the patent is not valid, or will not be infringed by the generic.
A statement from Warner Chilcott said: “The company is reviewing the detail of the paragraph IV notice from Barr, and continues to have full confidence in its intellectual property protecting Femcon Fe.”
Copyright © PA Business 2007
Warner Chilcott: www.warnerchilcott.com/index.php